R. Danzeisen

发表

Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment.

Karen Holmes, Kathy Lyons, Joseph Kessler, 2004, Bioorganic & medicinal chemistry letters.

A Critical Site in the Core of the CCR5 Chemokine Receptor Required for Binding and Infectivity of Human Immunodeficiency Virus Type 1*

M. Kavanaugh, Michael D. Miller, J. Lineberger, 1999, The Journal of Biological Chemistry.

Inhibition of HIV-1 Ribonuclease H by a Novel Diketo Acid, 4-[5-(Benzoylamino)thien-2-yl]-2,4-dioxobutanoic Acid*

D. Hazuda, Michael D. Miller, J. Cole, 2003, The Journal of Biological Chemistry.

HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb.

G. McGaughey, R. Freidinger, J. Shiver, 2003, Biochemistry.

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 4: synthesis of N-1 acidic functionality affording analogues with enhanced antiviral activity against HIV.

D. Hazuda, W. Schleif, E. Emini, 2002, Bioorganic & medicinal chemistry letters.

Syntheses and biological evaluation of 5-(piperidin-1-yl)-3-phenyl-pentylsulfones as CCR5 antagonists.

D. Hazuda, Ping Chen, W. Schleif, 2004, Bioorganic & medicinal chemistry letters.

Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds.

D. Hazuda, W. Schleif, E. Emini, 2004, Bioorganic & medicinal chemistry letters.

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists: modifications of the arylpropylpiperidine side chains.

D. Hazuda, Ping Chen, W. Schleif, 2003, Bioorganic & medicinal chemistry letters.

CCR5 antagonists: bicyclic isoxazolidines as conformationally constrained N-1-substituted pyrrolidines.

D. Hazuda, W. Schleif, E. Emini, 2002, Bioorganic & medicinal chemistry letters.

Combinatorial synthesis of CCR5 antagonists.

D. Hazuda, W. Schleif, E. Emini, 2001, Bioorganic & medicinal chemistry letters.

Synthesis and evaluation of CCR5 antagonists containing modified 4-piperidinyl-2-phenyl-1-(phenylsulfonylamino)-butane.

D. Hazuda, W. Schleif, E. Emini, 2005, Bioorganic & medicinal chemistry letters.

Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains.

Karen Holmes, Joseph Kessler, Anthony Carella, 2004, Bioorganic & medicinal chemistry letters.

Durhamycin A, a potent inhibitor of HIV Tat transactivation.

J. Tomassini, Z. Guan, O. Genilloud, 2002, Journal of natural products.

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 3: polar functionality and its effect on anti-HIV-1 activity.

D. Hazuda, W. Schleif, E. Emini, 2002, Bioorganic & medicinal chemistry letters.

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes.

E A Emini, D. Hazuda, W. Schleif, 2001, Bioorganic & medicinal chemistry letters.

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanes.

E A Emini, D. Hazuda, W. Schleif, 2001, Bioorganic & medicinal chemistry letters.

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes.

E A Emini, D. Hazuda, W. Schleif, 2001, Bioorganic & medicinal chemistry letters.

1,3,4 Trisubstituted pyrrolidine CCR5 receptor antagonists bearing 4-aminoheterocycle substituted piperidine side chains.

Karen Holmes, Joseph Kessler, Anthony Carella, 2003, Bioorganic & medicinal chemistry letters.

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity.

D. Hazuda, W. Schleif, E. Emini, 2001, Bioorganic & medicinal chemistry letters.

Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay.

G. Ciliberto, J. Shiver, W. Schleif, 2004, Journal of immunological methods.

Enhancement of α-Helicity in the HIV-1 Inhibitory Peptide DP178 Leads to an Increased Affinity for Human Monoclonal Antibody 2F5 but Does Not Elicit Neutralizing Responses in Vitro

J. Shiver, V. Garsky, M. Citron, 2002, The Journal of Biological Chemistry.

Altering Expression Levels of Human Immunodeficiency Virus Type 1 gp120-gp41 Affects Efficiency but Not Kinetics of Cell-Cell Fusion

D. Hazuda, A. Simon, J. Lineberger, 2002, Journal of Virology.

Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection.

D. Hazuda, W. Schleif, E. Emini, 2001, Bioorganic & medicinal chemistry letters.

Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection.

D. Hazuda, W. Schleif, E. Emini, 2001, Bioorganic & medicinal chemistry letters.